Annual Cash & Cash Equivalents
$34.65 M
-$3.09 M-8.18%
December 31, 2023
Summary
- As of February 12, 2025, KYTX annual cash & cash equivalents is $34.65 million, with the most recent change of -$3.09 million (-8.18%) on December 31, 2023.
- During the last 3 years, KYTX annual cash & cash equivalents has fallen by -$41.42 million (-54.45%).
- KYTX annual cash & cash equivalents is now -54.45% below its all-time high of $76.07 million, reached on December 1, 2021.
Performance
KYTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$104.66 M
-$26.95 M-20.48%
September 30, 2024
Summary
- As of February 12, 2025, KYTX quarterly cash and cash equivalents is $104.66 million, with the most recent change of -$26.95 million (-20.48%) on September 30, 2024.
- Over the past year, KYTX quarterly cash and cash equivalents has increased by +$70.02 million (+202.08%).
- KYTX quarterly cash and cash equivalents is now -53.34% below its all-time high of $224.29 million, reached on March 31, 2024.
Performance
KYTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
KYTX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.2% | +202.1% |
| 3 y3 years | -54.5% | +202.1% |
| 5 y5 years | -54.5% | +202.1% |
KYTX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -54.5% | at low | -53.3% | +355.7% |
| 5 y | 5-year | -54.5% | at low | -53.3% | +355.7% |
| alltime | all time | -54.5% | at low | -53.3% | +355.7% |
Kyverna Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $104.66 M(-20.5%) |
| Jun 2024 | - | $131.62 M(-41.3%) |
| Mar 2024 | - | $224.29 M(+547.3%) |
| Dec 2023 | $34.65 M | $34.65 M(+50.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $22.97 M(-39.1%) |
| Dec 2022 | $37.73 M(-50.4%) | - |
| Dec 2022 | - | $37.73 M |
| Dec 2021 | $76.07 M | - |
FAQ
- What is Kyverna Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Kyverna Therapeutics?
- What is Kyverna Therapeutics annual cash & cash equivalents year-on-year change?
- What is Kyverna Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Kyverna Therapeutics?
- What is Kyverna Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Kyverna Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of KYTX is $34.65 M
What is the all time high annual cash & cash equivalents for Kyverna Therapeutics?
Kyverna Therapeutics all-time high annual cash & cash equivalents is $76.07 M
What is Kyverna Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, KYTX annual cash & cash equivalents has changed by -$3.09 M (-8.18%)
What is Kyverna Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of KYTX is $104.66 M
What is the all time high quarterly cash and cash equivalents for Kyverna Therapeutics?
Kyverna Therapeutics all-time high quarterly cash and cash equivalents is $224.29 M
What is Kyverna Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, KYTX quarterly cash and cash equivalents has changed by +$70.02 M (+202.08%)